Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer, BMC Cancer
Résistance hormonale, méthylation et cancer du sein - CRCL
CRCL Centre de Recherche en Cancérologie de Lyon sur LinkedIn : Cancer du sein : vers une meilleure prise en charge des patientes traitées…
Long-term airborne dioxin exposure and breast cancer risk in a case-control study nested within the French E3N prospective cohort - CRCL-Résistance hormonale, méthylation et cancer du sein
Plateforme de Gestion des Echantillons Biologiques - PGEB - CRCL
Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα+ breast cancer
Free Radicals–Mediated Epigenetic Changes and Breast Cancer Progression
PDF) Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer
Cancers, Free Full-Text
Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα+ breast cancer
Cellular landscaping of cisplatin resistance in cervical cancer - ScienceDirect
Résistance hormonale, méthylation et cancer du sein - CRCL
Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα+ breast cancer
Regulation of DNA methylation by ERRα reveals a role for IRF4 in breast cancer
